IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC: RHHBY) concerning possible violations of federal securities laws.
If you purchased shares of Roche Holding and want more information, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
The investigation focuses on whether Roche Holding and certain of its officers and/or directors violated federal securities laws. On June 5, 2017, news reports stated that a new study showed that adding Roche Holding’s breast cancer drug Perjeta to its older treatment Herceptin only had a slight benefit while more than doubling the one-year treatment cost; and that the combination of Perjeta with Herceptin had higher rates of certain side effects than Herceptin alone, including severe diarrhea. When this information was released, shares of Roche Holding fell in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.